February 2023 tender notification
Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 88 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021 and the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 March 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
---|---|---|---|---|---|---|---|---|
Oxaliplatin1 |
Inj 5 mg per ml, 20 ml vial; 1 vial pack |
$46.32 |
$33.35 |
Alchemy Oxaliplatin |
5% |
1 May 2023 |
1 October 2023 |
Oxaliplatin Accord (Accord) |
1The price and subsidy of Oxaliplatin (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 May 2023. The subsidy of Oxaliplatin inj 1 mg for ECP (Baxter) will also be amended from $0.48 per 1 mg to $0.35 per 1 mg from 1 May 2023 |
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
2. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
---|---|---|---|---|---|---|
Anastrozole |
Tab 1 mg; 30 tablet blister pack |
$4.55 |
$4.39 |
Anatrole (Viatris) |
1 July 2023 |
1 December 2023 |
Betahistine dihydrochloride |
Tab 16 mg; 100 tablet blister pack |
$4.62 |
$3.70 |
Serc (Viatris) |
1 July 2023 |
1 December 2023 |
Bicalutamide |
Tab 50 mg; 28 tablet blister pack |
$4.21 |
$4.18 |
Binarex (Rex Medical) |
1 July 2023 |
1 December 2023 |
Exemestane |
Tab 25 mg; 30 tablet blister pack |
$14.50 |
$9.86 |
Pfizer Exemestane (Pfizer) |
1 June 2023 |
1 November 2023 |
Finasteride |
Tab 5 mg; 100 tablet blister pack |
$4.81 |
$4.79 |
Ricit (Rex Medical) |
1 July 2023 |
1 December 2023 |
Flecainide acetate |
Tab 50 mg; 60 tablet blister pack |
$19.95 |
$19.95 |
Flecainide BNM (Boucher) |
1 July 2023 |
1 December 2023 |
Hydroxyurea [hydroxy-carbamide]2 |
Cap 500 mg; 100 capsule blister pack |
$23.82 |
$20.72 |
Hydroxy-carbamide (Devatis) |
1 July 2023 |
1 December 2023 |
Leflunomide |
Tab 10 mg; 30 tablet bottle |
$6.00 |
$6.00 |
Arava (Sanofi) |
1 July 2023 |
1 December 2023 |
Leflunomide |
Tab 20 mg; 30 tablet bottle |
$6.00 |
$6.00 |
Arava (Sanofi) |
1 July 2023 |
1 December 2023 |
Levonorgestrel |
Subdermal implant (2 x 75 mg rods); 1 implant pack |
$106.92 |
$106.92 |
Jadelle (Bayer) |
1 July 2023 |
1 December 2023 |
Mebeverine hydrochloride |
Tab 135 mg; 90 tablet blister pack |
$9.20 |
$8.50 |
Colofac (Viatris) |
1 July 2023 |
1 December 2023 |
Nitrofurantoin2 |
Cap modified-release 100 mg; 100 capsule bottle |
$86.40 |
$81.20 |
Macrobid (Te Arai) |
1 July 2023 |
1 December 2023 |
Rifampicin |
Cap 150 mg; 100 capsule blister back |
$58.54 |
$58.54 |
Rifadin (Sanofi) |
1 July 2023 |
1 December 2023 |
Rifampicin |
Cap 300 mg; 100 capsule blister pack |
$122.06 |
$122.06 |
Rifadin (Sanofi) |
1 July 2023 |
1 December 2023 |
Rifampicin |
Oral liq 100 mg per 5 ml; 60 ml bottle pack |
$12.60 |
$12.60 |
Rifadin (Sanofi) |
1 July 2023 |
1 December 2023 |
Tacrolimus |
Oint 0.1%; 30 g tube OP |
$33.00 |
$33.00 |
Zematop (Douglas) |
1 July 2023 |
1 December 2023 |
Tamoxifen citrate2 |
Tab 10 mg; 60 tablet blister pack |
$15.00 |
$15.00 |
Tamoxifen Sandoz (Sandoz) |
1 July 2023 |
1 December 2023 |
Tamoxifen citrate2 |
Tab 20 mg; 60 tablet blister pack |
$6.65 |
$5.32 |
Tamoxifen Sandoz (Sandoz) |
1 July 2023 |
1 December 2023 |
Tobramycin |
Solution for inhalation 60 mg per ml, 5 ml; 56 plastic ampoule/nebuliser |
$395.00 |
$395.00 |
Tobramycin BNM (Boucher) |
1 July 2023 |
1 December 2023 |
2This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2022/23 Invitation To Tender. |
3. Tenders awarded to pharmaceuticals where at least one other brand is listed
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
---|---|---|---|---|---|---|---|
Ambrisentan |
Tab 5 mg; 30 tablet bottle |
$1,550.00 |
$200.00 |
Ambrisentan Viatris (Viatris) |
1 July 2023 |
1 December 2023 |
Mylan (Viatris) |
Ambrisentan |
Tab 10 mg; 30 tablet bottle |
$1,550.00 |
$200.00 |
Ambrisentan Viatris (Viatris) |
1 July 2023 |
1 December 2023 |
Mylan (Viatris) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
4. Tenders awarded to Pharmaceuticals where no other brand is listed
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Date of price change |
Principal Supply date |
---|---|---|---|---|---|---|---|
Anastrozole |
Tab 1 mg; 30 tablet blister pack |
$4.55 |
$4.39 |
Anatrole (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Betahistine dihydrochloride |
Tab 16 mg; 100 tablet blister pack |
$4.62 |
$3.70 |
Serc (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Bicalutamide |
Tab 50 mg; 28 tablet blister pack |
$4.21 |
$4.18 |
Binarex (Rex Medical) |
5% |
1 July 2023 |
1 December 2023 |
Cefotaxime |
Inj 1 g vial; 10 vial carton |
$45.00 |
$38.98 |
DBL Cefotaxime (Pfizer) |
5% |
1 July 2023 |
1 November 2023 |
Exemestane |
Tab 25 mg; 30 tablet blister pack |
$14.50 |
$9.86 |
Pfizer Exemestane (Pfizer) |
5% |
1 June 2023 |
1 November 2023 |
Finasteride |
Tab 5 mg; 100 tablet blister pack |
$4.81 |
$4.79 |
Ricit (Rex Medical) |
5% |
1 July 2023 |
1 December 2023 |
Flecainide acetate |
Tab 50 mg; 60 tablet blister pack |
$19.95 |
$19.95 |
Flecainide BNM (Boucher) |
5% |
1 July 2023 |
1 December 2023 |
Hydroxyurea [hydroxy- |
Cap 500 mg; 100 capsule blister pack |
$23.82 |
$20.72 |
Hydroxy-carbamide (Devatis) |
5% |
1 July 2023 |
1 December 2023 |
Leflunomide |
Tab 10 mg; 30 tablet bottle |
$6.00 |
$6.00 |
Arava (Sanofi) |
5% |
1 July 2023 |
1 December 2023 |
Leflunomide |
Tab 20 mg; 30 tablet bottle |
$6.00 |
$6.00 |
Arava (Sanofi) |
5% |
1 July 2023 |
1 December 2023 |
Levonorgestrel |
Subdermal implant (2 x 75 mg rods); 1 |
$106.92 |
$106.92 |
Jadelle (Bayer) |
5% |
1 July 2023 |
1 December 2023 |
Mebeverine hydrochloride |
Tab 135 mg; 90 tablet blister pack |
$9.20 |
$8.50 |
Colofac (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Methotrexate3, 4 |
Inj 100 mg per ml, 50 ml vial; 1 vial pack |
$79.99 |
$67.99 |
Methotrexate Ebewe (Sandoz) |
5% |
1 July 2023 |
1 December 2023 |
Metronidazole |
Inj 5 mg per ml, 100 ml; 10 bag pack |
$27.50 |
$18.00 |
Baxter Metronidazole (Baxter) |
5% |
1 July 2023 |
1 December 2023 |
Nitrofurantoin3 |
Cap modified-release 100 mg; 100 |
$86.40 |
$81.20 |
Macrobid (Te Arai) |
5% |
1 July 2023 |
1 December 2023 |
Rifampicin |
Cap 150 mg; 100 capsule blister back |
$58.54 |
$58.54 |
Rifadin (Sanofi) |
5% |
1 July 2023 |
1 December 2023 |
Rifampicin |
Cap 300 mg; 100 capsule blister pack |
$122.06 |
$122.06 |
Rifadin (Sanofi) |
5% |
1 July 2023 |
1 December 2023 |
Rifampicin |
Inj 600 mg vial; 1 powder for injection |
$134.98 |
$134.98 |
Rifadin (Sanofi) |
5% |
1 July 2023 |
1 December 2023 |
Rifampicin |
Oral liq 100 mg per 5 ml; 60 ml bottle |
$12.60 |
$12.60 |
Rifadin (Sanofi) |
5% |
1 July 2023 |
1 December 2023 |
Tacrolimus |
Oint 0.1%; 30 g tube |
$33.00 |
$33.00 |
Zematop (Douglas) |
5% |
1 July 2023 |
1 December 2023 |
Tamoxifen citrate3 |
Tab 10 mg; 60 tablet blister pack |
$15.00 |
$15.00 |
Tamoxifen Sandoz (Sandoz) |
5% |
1 July 2023 |
1 December 2023 |
Tamoxifen citrate3 |
Tab 20 mg; 60 tablet blister pack |
$6.65 |
$5.32 |
Tamoxifen Sandoz (Sandoz) |
5% |
1 July 2023 |
1 December 2023 |
Tobramycin |
Solution for inhalation 60 mg per ml, |
$395.00 |
$395.00 |
Tobramycin BNM (Boucher) |
5% |
1 July 2023 |
1 December 2023 |
3This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4, clause 2.3 (c)(ii) of the 2022/23 Invitation To Tender. 4The price and subsidy of methotrexate (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2023. |
5. Tenders awarded to pharmaceuticals where at least one other brand is listed
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
---|---|---|---|---|---|---|---|---|
Ambrisentan |
Tab 5 mg; 30 tablet bottle |
$1,550.00 |
$200.00 |
Ambrisentan Viatris (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Mylan (Viatris) |
Ambrisentan |
Tab 10 mg; 30 tablet bottle |
$1,550.00 |
$200.00 |
Ambrisentan Viatris (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Mylan (Viatris) |
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2022/23 Invitation to Tender, dated 31 October 2022.
Chemical name |
Line item |
---|---|
Benzatropine mesylate |
Inj 1 mg per ml, 2 ml ampoule |
Cyproterone acetate with ethinyloestradiol |
Tab 2 mg with ethinyloestradiol 35 mcg |
Glycagon hydrochloride |
Inj 1 mg syringe kit |
Metaraminol tartrate |
Inj 1 mg per ml, 1 ml |
Metaraminol tartrate |
Inj 1 mg per ml, 10 ml |
Noradrenaline |
Inj 0.1 mg per ml, 100 ml bag |
Noradrenaline |
Inj 0.12 mg per ml, 100 ml bag |
Noradrenaline |
Inj 0.16 mg per ml, 50 ml syringe |
Tacrolimus (widened access) |
Oint 0.1%, 30 g |
For products included in the 2020/21, 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.